Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017 Jul;13(4):207-20. doi: 10.5055/jom.2017.0389
Ronquest N, Wollschlaeger B, Montejano L, Wilson T, Nadipelli V. Characteristics and treatment patterns of US medicaid patients with opioid use disorder. Poster presented at the 2016 International Conference on Opioids Conference; June 2016. Boston, MA. [abstract] J Opioid Manag. 2016 May; 12(3):227.
Luciano JV, Barrada JR, Aguado J, Osma J, García-Campayo J. Bifactor analysis and construct validity of the HADS: a cross-sectional and longitudinal study in fibromyalgia patients. Psychological Assessment. 2014 Jun;26(2):395-406.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.